Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tacrolimus and Sirolimus for GVHD Prophylaxis in Non-myeloablative PBSCT
NCT00282282Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jan 2006
- Primary completion
- Jan 2009
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of tacrolimus + Wuzhi capsule, sirolimus in graft-versus-host disease (GVHD), sponsored by Dana-Farber Cancer Institute. Started Jan 2006; status: completed.
02
Drugs
tacrolimus + Wuzhi capsulesirolimus
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT00282282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00282282.